The effect of nerve growth factor and antibodies to nerve growth factor on ethylnitrosourea-induced neoplastic proliferation in rat trigeminal nerves.
Sprague-Dawley (CD) rats were injected intravenously with ethylnitrosourea at a dose of 20 mg/kg on day 20 of gestation. This exposure resulted in early neoplastic proliferation or development of a neurinoma of the trigeminal nerve in 58% of the offspring at 90 days of age. Implantation of osmotic microinfusion pumps containing 2.5S nerve growth factor prior to ethylnitrosourea administration significantly reduced the incidence of early neoplastic proliferation. Postnatal implantation of microinfusion pumps containing 2.5S nerve growth factor also resulted in a significant but less pronounced reduction of early neoplastic proliferation. Immunoglobulin G directed against nerve growth factor (anti-nerve growth factor) did not influence the incidence of early neoplastic proliferation when administered via microinfusion pumps implanted on day 15 postnatally. These findings suggest that nerve growth factor has a protective effect on the developing nervous system against ethylnitrosourea-induced carcinogenesis.
D000818:Animals; D000906:Antibodies; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D003390:Cranial Nerve Neoplasms / Q000139:chemically induced* / Q000151:congenital / Q000473:pathology; D005038:Ethylnitrosourea; D005260:Female; D008297:Male; D051379:Mice; D009414:Nerve Growth Factors / Q000276:immunology / Q000494:pharmacology*; D009442:Neurilemmoma / Q000139:chemically induced* / Q000151:congenital / Q000473:pathology; D009607:Nitrosourea Compounds; D011247:Pregnancy; D051381:Rats; D011919:Rats, Inbred Strains; D014276:Trigeminal Nerve
D000906:Antibodies; D009414:Nerve Growth Factors; D009607:Nitrosourea Compounds; D005038:Ethylnitrosourea